Aquestive Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

Aquestive Therapeutics

04/11/2023 03:01

* Aquestive Therapeutics Inc  AQST.OQ   AQST.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The Warren New Jersey-based  company is expected to report
 a
0.4% increase in revenue to $11.514 million from $11.46 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Aquestive
Therapeutics
Inc is for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aquestive
Therapeutics Inc is $6​, above​ its last closing price of $1.60.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.12       -0.12      -0.10     Beat    15.3
 Mar. 31 2023  -0.18       -0.19      -0.12     Beat    36.5
 Dec. 31 2022  -0.21       -0.23      -0.23     Met     0.3​
 Sep. 30 2022  -0.31       -0.31      -0.23     Beat    26.3
 ​​Jun.        -0.36       -0.36      -0.36     Met     0
 30 2022                                                
 Mar. 31 2022  -0.39       -0.41      -0.32     Beat    21.6​
 Dec. 31 2021  -0.42       -0.47      -0.38     Beat    18.7
 Sep. 30 2021  -0.43       -0.45      -0.37     Beat    17.8
 This summary was machine generated November 4 at 03:01 GMT.  All
figures in US dollars  unless otherwise stated